Corvus Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.

About CRVS

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. 

CEO
Richard A. Miller
CEORichard A. Miller
Employees
31
Employees31
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2014
Founded2014
Employees
31
Employees31

CRVS Key Statistics

Market cap
1.42B
Market cap1.42B
Price-Earnings ratio
-31.59
Price-Earnings ratio-31.59
Dividend yield
Dividend yield
Average volume
1.04M
Average volume1.04M
High today
$17.07
High today$17.07
Low today
$16.24
Low today$16.24
Open price
$16.59
Open price$16.59
Volume
704.27K
Volume704.27K
52 Week high
$26.95
52 Week high$26.95
52 Week low
$2.54
52 Week low$2.54

Stock Snapshot

The current Corvus Pharmaceuticals(CRVS) stock price is $16.90, with a market capitalization of 1.42B. The stock trades at a price-to-earnings (P/E) ratio of -31.59.

On 2026-03-12, Corvus Pharmaceuticals(CRVS) stock moved within a range of $16.24 to $17.07. With shares now at $16.90, the stock is trading +4.1% above its intraday low and -1.0% below the session's peak.

Trading activity shows a volume of 704.27K, compared to an average daily volume of 1.04M.

The stock's 52-week range extends from a low of $2.54 to a high of $26.95.

The stock's 52-week range extends from a low of $2.54 to a high of $26.95.

CRVS News

Simply Wall St 3d
Is Corvus Pharmaceuticals Now Attractive After Recent Share Price Volatility?

If you are wondering whether Corvus Pharmaceuticals' recent share price puts it at a bargain or a stretched level, you are not alone. This article is here to un...

Is Corvus Pharmaceuticals Now Attractive After Recent Share Price Volatility?
TipRanks 6d
Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch

Corvus Pharmaceuticals Inc. (CRVS) announced an update on their ongoing clinical study. The Phase 2 SIERRA1 study, officially titled “A Phase 2 Multicenter, Ra...

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CRVS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.